However, hypoglycemia risk increases when these agents are combined with insulin or insulin secretagogues, necessitating dose adjustments of concomitant medications in many cases
Nutritional markers should be selected according to intake, symptoms, and weight-loss trajectory
According to the FDA, one of the potential concerns is that the compounded drug may contain the incorrect amount of an active ingredient, leading to adverse effects
While these do not predict exact medication response, they may help your provider contextualize your metabolic profile and decide whether liraglutide, semaglutide, tirzepatide, or another approach aligns with your genetics and health goals
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for type 2 diabetes management that have demonstrated significant weight loss effects
You get continuous support, structure, and clarity throughout your journey